Solutionreach vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (80 vs 74)
Solutionreach logo

Solutionreach

LeaderHealthtech

Patient Engagement Platform

Patient engagement and communication platform for dental, medical, and optical practices with 400+ PMS integrations. Lehi UT; founded 2000;

AI VisibilityBeta
Overall Score
B74
Category Rank
#87 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
70
Perplexity
77
Gemini
72

About

Solutionreach is a Lehi, Utah-based patient engagement platform that has served dental, medical, optometry, and specialty healthcare practices with automated appointment reminders, patient messaging, satisfaction surveys, and online review management since 2000. As one of the earliest companies to build technology specifically for healthcare practice patient communication, Solutionreach has established a large installed base across independent practices and group practices in the United States. The platform integrates with over 400 practice management and EHR systems, triggering automated patient communication workflows based on appointment data, recall schedules, and clinical events—without requiring manual staff intervention for each individual patient interaction.\n\nSolutionreach's patient retention capabilities are central to its value proposition for healthcare practices. Research consistently shows that automated recall outreach significantly increases the percentage of patients who return for follow-up care and preventive appointments, and Solutionreach's multi-channel recall sequences—combining text, email, and phone reminders sent at configurable intervals—help practices reduce the attrition that erodes practice revenue over time. The platform's satisfaction survey module automatically collects patient feedback after appointments and routes positive responses to review sites while flagging negative feedback for internal service recovery, helping practices manage their online reputation systematically.\n\nSolutionreach has expanded its platform with online scheduling, telehealth integration, and digital patient intake forms to address the growing patient expectation for digital access to healthcare services. The company also offers practice benchmarking through aggregated data insights that allow practices to compare their recall rates, no-show rates, and online review volumes against peers in their specialty and geography. Solutionreach competes with Weave, Lighthouse 360, and RevenueWell in the dental and multi-specialty patient engagement market, differentiating on its depth of EHR and PMS integrations and its long track record with independent practice customers.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

74
Overall Score
80
#87
Category Rank
#18
75
AI Consensus
83
stable
Trend
stable
70
ChatGPT
78
77
Perplexity
78
72
Gemini
80
78
Claude
84
69
Grok
77

Key Details

Category
Patient Engagement Platform
Enterprise
Tier
Leader
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Solutionreach
Patient Engagement Platform

Integrations

Only Solutionreach
Only Bristol Myers Squibb
Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.